معرفی
apl. Prof. Dr. Miriam Breunig is Associate Professor (apl. Prof.) of Pharmaceutical Technology at the University of Regensburg, Germany, and heads a research group developing nanoparticle-based drug- and vaccine-delivery systems. Since 2023 she serves as Co-Editor-in-Chief of the European Journal of Pharmaceutics and Biopharmaceutics and in 2024 was appointed Galenus Foundation Guest Professor at MIT.
Education & Career:
- 1996-2001: Undergraduate pharmacy studies, Ruprecht-Karls-University Heidelberg
- 2002-2005: Graduate researcher, Univ. Regensburg (Prof. Göpferich)
- 2008 & 2009: Post-doctoral fellow, MIT (Prof. Robert Langer)
- 2013: Habilitation in Pharmaceutical Technology, Univ. Regensburg
- since 2012: Akademische Rätin (Associate Professor), Dept. Pharmaceutical Technology, Univ. Regensburg
Research Focus: The Breunig group engineers innovative delivery platforms for small molecules, proteins and nucleic acids. Core projects include silica- and mesoporous-silica nanoparticle vaccines against HIV-1 and SARS-CoV-2, injectable hydrogels that provide sustained nanoparticulate antigen release for single-dose immunisation, and nanoparticle-based glaucoma therapy targeting the trabecular meshwork/Schlemm's canal with siRNA or ROCK inhibitors.
Publication Trends: Recent articles (2020-2024) concentrate on multivalent antigen display on silica nanoparticles to enhance B-cell activation and durable antibody responses, long-acting hydrogel depots for HIV vaccines, ocular nanoparticle targeting for glaucoma, and mechanistic studies on nanoparticle functionalisation, ECM penetration and controlled release.
Editorial & Honours:
- Co-Editor-in-Chief, Eur J Pharm Biopharm (since 2023)
- Co-Editor, same journal (2013-2023)
- Galenus Foundation Guest Professor, MIT (2024)
Collaborations & Funding: She coordinates projects within the HIVacToGC consortium, collaborates with Prof. Mika Lindén (mesoporous silica), Prof. Rudolf Fuchshofer (ocular pharmacology) and partners at MIT, and has secured funding for vaccine and glaucoma nanomedicine initiatives.
